6:25 PM
 | 
Jan 23, 2013
 |  BC Extra  |  Company News

Alexion falls on delayed U.K. reimbursement decision

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) fell $4.44 to $92.96 on Wednesday after it said the U.K. Ministers of Health deferred a decision to cover Soliris eculizumab on the NHS for atypical hemolytic uremic syndrome (aHUS). According to the...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >